April 2018 - Cancer Currents Blog
- Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival
Researchers compared the risk of death for women with breast cancer who had low skeletal muscle mass, or sarcopenia, at the time of their cancer diagnosis and women who had adequate muscle mass.
- Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer
Results from a large clinical trial show combining an immune checkpoint inhibitor with chemotherapy helped some patients with advanced lung cancer live longer than chemotherapy alone. How will this change the lung cancer treatment landscape?
- Cancer Control in American Indian and Alaska Native Populations: A Conversation with Dr. Shobha Srinivasan
American Indian and Alaska Native populations are disproportionately affected by certain cancers. In this interview, Dr. Shobha Srinivasan discusses some of these disparities and programs funded by NCI that are helping to address them.
- Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug
In a small clinical trial, researchers compared the efficacy of a much lower dose of the cancer drug abiraterone (Zytiga) taken with a low-fat breakfast with a full dose taken on an empty stomach, as directed on the drug’s label.
- NCI Expands Repository of Cancer Research Models: A Conversation with Drs. Doroshow and Evrard
NCI is expanding its Patient-Derived Models Repository (PDMR), which provides cancer research models made directly from human tumor tissue. In this Q&A, Drs. Yvonne Evrard and James Doroshow explain how the new models can help cancer researchers make more rapid progress.
- Brentuximab Approved for Initial Treatment of Advanced Hodgkin Lymphoma
The FDA has expanded the approved uses of brentuximab (Adcetris) in people with Hodgkin lymphoma. Under the new approval, brentuximab can be used in combination with three other chemotherapy drugs as an initial treatment in patients with advanced disease.
- Interactive App Improves Colorectal Cancer Screening Rates
Colorectal cancer screening reduces deaths from the disease, yet about one-third of Americans aren’t up to date with screening. Learn what happened when people waiting for routine checkups used an app that allowed them to order their own screening test.
- Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response
Two independent groups of researchers have fused a TGF-beta receptor to a monoclonal antibody that targets a checkpoint protein. The result is a single hybrid molecule called a Y-trap that blocks two pathways used by tumors to evade the immune system.
- NCI Launches New Resource for Specimens and Data from Cancer Clinical Trials
NCI has launched Navigator, a new resource for researchers interested in using specimens and clinical data collected from large cancer clinical trials.